SGS742 in Patients With Mild to Moderate Alzheimer's Disease (AD)
NCT ID: NCT00093951
Last Updated: 2009-12-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
280 participants
INTERVENTIONAL
2004-04-30
2007-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SGS742
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with mild to moderate Alzheimer's disease
* Willing caregiver
* In general good health
Exclusion Criteria
Prohibited Meds:
* Alzheimer's medications (Aricept, Exelon, Remydl, Nemenda)
55 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Saegis Pharmaceuticals
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Phoenix, Arizona, United States
Dedicated Clinical Research
Sun City, Arizona, United States
Northwest NeuroSpecialists, PLLC
Tucson, Arizona, United States
Clinical Trials Incorporated
Little Rock, Arkansas, United States
Margolin Brain Institute
Fresno, California, United States
NervePro Research
Irvine, California, United States
Center for Neurologic Studies
La Jolla, California, United States
Neuro Therapeutics, Inc.
Pasadena, California, United States
Pacific Research Network, Inc.
San Diego, California, United States
Affiliated Research Institute
San Diego, California, United States
San Francisco Clinical Research Center
San Francisco, California, United States
Southern California Clinical Research, Inc.
San Marino, California, United States
The Mile High Research Center
Denver, Colorado, United States
Research Center for Clinical Studies, Inc.
Darien, Connecticut, United States
Stamford, Connecticut, United States
Baumel-Eisner Neuromedical Institute, Inc.
Boca Raton, Florida, United States
Bradenton Neurology, Inc.
Bradenton, Florida, United States
Brain Matters, Inc.
Delray Beach, Florida, United States
Baumel-Eisner Neuromedical Institute
Fort Lauderdale, Florida, United States
Berma Research Group
Hialeah, Florida, United States
Allied Clinical Trials, The Neurology Group
Miami, Florida, United States
Tukoi Institute for Clinical Research
Miami, Florida, United States
Baumel-Eisner Neuromedical Institute
Miami Beach, Florida, United States
Ocala Neurodiagnostic Center
Ocala, Florida, United States
Orange City, Florida, United States
Palm Springs, Florida, United States
Pompano Beach, Florida, United States
Tampa, Florida, United States
Tampa, Florida, United States
CSI Research
Decatur, Georgia, United States
DeKalb Neurology Associates, LLC
Decatur, Georgia, United States
MidAmerica Neuroscience Institute
Lenexa, Kansas, United States
Neurology Department, LSU Health Sciences Center
Shreveport, Louisiana, United States
Baystate Medical Center
Springfield, Massachusetts, United States
SW Medical Associates
Las Vegas, Nevada, United States
Paterson, New Jersey, United States
Psychopharmacology Research Association of Princeton, P.C.
Princeton, New Jersey, United States
United Health Services Office of Clinical Trials
Johnson City, New York, United States
New York, New York, United States
Raleigh Neurology
Raleigh, North Carolina, United States
Raleigh, North Carolina, United States
Winston-Salem, North Carolina, United States
MetroHealth Medical Center
Cleveland, Ohio, United States
University Memory and Aging Center
Cleveland, Ohio, United States
Toledo, Ohio, United States
Lynn Health Science Institute
Oklahoma City, Oklahoma, United States
Oregon Center for Clinical Investigations, Inc.
Eugene, Oregon, United States
Medford, Oregon, United States
Bala-Cynwyd, Pennsylvania, United States
The Clinical Trial Center, LLC
Jenkintown, Pennsylvania, United States
RI Mood & Memory Research Institute
East Providence, Rhode Island, United States
Madison, Tennessee, United States
Senior Adults Specialty Research, Inc.
Austin, Texas, United States
Claghorn-Lesem Research Clinic, Ltd.
Bellaire, Texas, United States
Radiant Research San Antonio
San Antonio, Texas, United States
Texas Medical Research Associates, LLC
San Antonio, Texas, United States
Grayline Clinical Drug Trials
Wichita Falls, Texas, United States
Bennington, Vermont, United States
National Clinical Research, Inc.
Richmond, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Froestl W, Gallagher M, Jenkins H, Madrid A, Melcher T, Teichman S, Mondadori CG, Pearlman R. SGS742: the first GABA(B) receptor antagonist in clinical trials. Biochem Pharmacol. 2004 Oct 15;68(8):1479-87. doi: 10.1016/j.bcp.2004.07.030.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IA0061
Identifier Type: -
Identifier Source: org_study_id